ArticleJournal of the Endocrine Society2026
Preventive effect of prednisolone on permanent hypothyroidism in subacute thyroiditis: retrospective study of 743 cases.
Article in Journal of the Endocrine Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Permanent hypothyroidism (PH) after subacute thyroiditis (SAT) requires lifelong thyroid hormone replacement therapy. This study aimed to investigate the risk factors for PH and its association with treatment. Methods: A retrospective observational study of 743 patients diagnosed with SAT from 2016 to 2019 was conducted. Results: Initial treatment was prednisolone (PSL) in 332 patients (44.7%), nonsteroidal anti-inflammatory drugs (NSAIDs) in 364 (49.0%), and rest without medication in 47 (6.3%). Of the NSAID-treated patients, 238 (65.4%) switched to PSL. Final treatment was PSL in 570 (76.7%), NSAIDs in 126 (17.0%), and rest in 47 (6.3%). Permanent hypothyroidism occurred in 32 patients (4.3%). Prednisolone therapy was used less frequently in the PH group (46.9%) than in the euthyroid group (78.1%, Conclusion: Prednisolone therapy for SAT helps prevent PH through its anti-inflammatory effects. In younger patients, early PSL therapy may be preferable to reduce the risk of PH, as PH requires long-term levothyroxine therapy. In elderly patients, NSAIDs were often sufficient, whereas PSL therapy may be considered when clinically indicated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.